Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis

Liberato NL, Rognoni C, Rubrichi S, Quaglini S, Marchetti M, Gorlia T, Licitra L, Vermorken JB

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1093/annonc/mdr545

Original Paper URL
http://annonc.oxfordjournals.org/content/23/7/1825.abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Squamous Cell /drug therapy /mortality; Cisplatin /administration & dosage; Cost-Benefit Analysis; Decision Support Techniques; Fluorouracil /administration & dosage; Head and Neck Neoplasms /drug therapy /mortality; Induction Chemotherapy /economics; Markov Chains; Monte Carlo Method; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Taxoids /administration & dosage

AccessionNumber
22012031567

Date bibliographic record published
17/10/2012